What is the consensus rating for FPRX stock?
The consensus rating for Five Prime Thera (FPRX) is 75 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Five Prime Thera (FPRX) Forecast, Price Target & Analyst Ratings
NASDAQ:FPRX
Current stock price
38
+0.01 (+0.03%)
At close:
38
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Five Prime Thera (FPRX).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $38.00 to mean target of N/A, Based on 8 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
75.00%
FPRX was analyzed by 8 analysts. The buy percentage consensus is at 75. So analysts seem to be have mildly positive about FPRX.
In the previous month the buy percentage consensus was at a similar level.
FPRX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A